Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy

References

• Focosi D, Franchini M, Pirofski LA, et al. COVID-19 convalescent plasma is more than neutralizing antibodies: a narrative review of potential beneficial and detrimental co-factors. Viruses. 2021;13(8):1594. DOI:10.3390/v13081594
   PubMed Web of Science ®Google Scholar
• Bihariesingh-Sanchit R, Bansie R, Ramdhani N, et al. Reduced Mortality among COVID-19 ICU patients after treatment with hemoclear convalescent plasma in suriname. MBio. 2023;14(2). DOI:10.1128/mbio.03379-22.
   PubMedGoogle Scholar
• Focosi D, Franchini M, Pirofski LA, et al. COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes. Clin Microbiol Rev. 2022;35:e0020021.
   PubMed Web of Science ®Google Scholar
• Senefeld JW, Gorman EK, Johnson PW, et al. Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma a Systematic review and meta-analysis. medRxiv. 2023. 2023.2001.2011.23284347.
   Google Scholar
• Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995;21(1):150–161.
   PubMed Web of Science ®Google Scholar
• Luke TC, Casadevall A, Watowich SJ, et al. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med. 2010;38(4 Suppl):e66–73.
   PubMedGoogle Scholar
• Gallagher JR. Use of convalescent measles serum to control measles in a preparatory school. Am J Public Health. 1935;25(5):595–598.
   Google Scholar
• Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Investig. 2020;130(4):1545–1548.
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA, Joyner MJ. The principles of antibody therapy for infectious diseases with relevance for COVID-19. MBio. 2021;12(2). DOI:10.1128/mBio.03372-20
   Web of Science ®Google Scholar
• CECIL RL. Effects of very early serum treatment in pneumococcus type I pneumonia. J Am Med Assoc. 1937;108(9):689–692.
   Google Scholar
• Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371:m3939.
   PubMed Web of Science ®Google Scholar
• Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384(7):619–629. DOI:10.1056/NEJMoa2031304
   PubMed Web of Science ®Google Scholar
• Abani O, Abbas A, Abbas F. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397(10289):2049–2059.
   PubMed Web of Science ®Google Scholar
• Hamilton FW, Lee T, Arnold DT, et al. Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial. Int J Infect Dis. 2021;109:114–117.
   PubMed Web of Science ®Google Scholar
• Menichetti F, Popoli P, Puopolo M, et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 Pneumonia: a Randomized Clinical Trial. JAMA Netw Open. 2021;4(11):e2136246. DOI:10.1001/jamanetworkopen.2021.36246
   PubMed Web of Science ®Google Scholar
• Franchini M, Focosi D, Casadevall A, et al. Convalescent plasma for COVID-19. TSUNAMI is not the final word. Eur J Internal Med. 2022;97:116–118.
   PubMed Web of Science ®Google Scholar
• Estcourt LJ, Turgeon AF, McQuilten ZK, et al. Effect of convalescent plasma on organ support-free days in critically Ill Patients with COVID-19: a Randomized Clinical Trial. JAMA. 2021;326(17):1690–1702. DOI:10.1001/jama.2021.18178
   PubMed Web of Science ®Google Scholar
• Begin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Med. 2021;27(11):2012–2024. DOI:10.1038/s41591-021-01488-2
   PubMed Web of Science ®Google Scholar
• Ortigoza MB, Yoon H, Goldfeld KS, et al. Efficacy and Safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical Trial. JAMA Intern Med. 2022;182(2):115–126. DOI:10.1001/jamainternmed.2021.6850
   PubMed Web of Science ®Google Scholar
• Casadevall A, Henderson JP. COVID-19 convalescent plasma and concomitant therapies in PassITON. Chest. 2022;162(5):e284–285.
   PubMed Web of Science ®Google Scholar
• Kunze KL, Johnson PW, van Helmond N, et al. Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors. Nat Commun. 2021;12(1):4864. DOI:10.1038/s41467-021-25113-5
   PubMed Web of Science ®Google Scholar
• Self WH, Wheeler AP, Stewart TG, et al. Neutralizing COVID-19 convalescent plasma in adults hospitalized with COVID-19: a blinded, randomized, placebo-controlled trial. Chest. 2022;162(5):982–994. DOI:10.1016/j.chest.2022.06.029
   PubMed Web of Science ®Google Scholar
• Ullah I, Beaudoin-Bussières G, Symmes K, et al. The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. Cell Reports Medicine. 2023;4(1):100893. DOI:10.1016/j.xcrm.2022.100893
   PubMedGoogle Scholar
• Natarajan H, Crowley AR, Butler SE, et al. Markers of Polyfunctional SARS-CoV-2 antibodies in convalescent plasma. MBio. 2021;12(2).
   PubMed Web of Science ®Google Scholar
• Herman JD, Wang C, Loos C, et al. Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. Nat Commun. 2021;12(1):6853. DOI:10.1038/s41467-021-27201-y
   PubMed Web of Science ®Google Scholar
• Marconato M, Abela IA, Hauser A, et al. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. J Clin Investig. 2022;132(12).
   PubMed Web of Science ®Google Scholar
• Benner SE, Patel EU, Laeyendecker O, et al. SARS-CoV-2 Antibody Avidity Responses in COVID-19 patients and convalescent plasma Donors. J Infect Dis. 2020;222(12):1974–1984. DOI:10.1093/infdis/jiaa581
   PubMed Web of Science ®Google Scholar
• Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490–9496. DOI:10.1073/pnas.2004168117
   PubMed Web of Science ®Google Scholar
• Sullivan DJ, Focosi D, Hanley D, et al. Outpatient regimens to reduce COVID-19 hospitalizations: a systematic review and meta-analysis of randomized controlled trials. medRxiv. 2022;2005.2024.22275478 (2022).
   Google Scholar
• Zimmerli A, Monti M, Fenwick C, et al. Case report: stepwise anti-inflammatory and anti-SARS-CoV-2 effects following convalescent plasma therapy with full clinical recovery. Front Immunol. 2021;12:613502.
   PubMed Web of Science ®Google Scholar
• Alsharidah S, Ayed M, Ameen RM, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: a multicenter interventional study. Int J Infect Dis. 2020;103:439–446.
   PubMed Web of Science ®Google Scholar
• Cognasse F, Hamzeh-Cognasse H, Rosa M, et al. Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study. EBioMedicine. 2023;87:104414.
   PubMed Web of Science ®Google Scholar
• Bandopadhyay P, D’Rozario R, Lahiri A, et al. Nature and dimensions of systemic hyperinflammation and its attenuation by convalescent plasma in Severe COVID-19. J Infect Dis. 2021;224(4):565–574. DOI:10.1093/infdis/jiab010
   PubMed Web of Science ®Google Scholar
• Acosta-Ampudia Y, Monsalve DM, Rojas M, et al. COVID-19 convalescent plasma composition and immunological effects in severe patients. J Autoimmun. 2021;118:102598.
   PubMed Web of Science ®Google Scholar
• Körper S, Schrezenmeier EV, Rincon-Arevalo H, et al. Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19. Front Immunol. 2022;13:1008438.
   PubMed Web of Science ®Google Scholar
• Mink S, List W, Hoefle G, et al. Evaluation of SARS-CoV-2 antibody levels on hospital admission as a correlate of protection against mortality. J Intern Med. 2023. DOI:10.1111/joim.13606.
   Web of Science ®Google Scholar
• Sullivan HC, Roback JD. Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 Pandemic. Transfus Med Rev. 2020;34(3):145–150.
   PubMed Web of Science ®Google Scholar
• Dzik S. COVID-19 convalescent plasma: now is the time for better science. Transfus Med Rev. 2020;34(3):141–144.
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Investig. 2020;130(9):4791–4797. DOI:10.1172/JCI140200
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Bruno KA, Klassen SA, et al. Safety Update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. 2020;95:1888–1895.
   PubMed Web of Science ®Google Scholar
• Senefeld JW, Johnson PW, Kunze KL, et al. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: a national registry study. PLOS Med. 2021;18(12):e1003872. DOI:10.1371/journal.pmed.1003872
   PubMed Web of Science ®Google Scholar
• Shoham S, Bloch EM, Casadevall A, et al. Transfusing convalescent plasma as post-exposure prophylaxis against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a double-blinded, phase 2 randomized, controlled trial. Clin Infect Dis. 2023;76(3):e477–486. DOI:10.1093/cid/ciac372
   PubMedGoogle Scholar
• Sullivan DJ, Gebo KA, Shoham S, et al. Early outpatient treatment for covid-19 with convalescent plasma. N Engl J Med. 2022;386(18):1700–1711. DOI:10.1056/NEJMoa2119657
   PubMed Web of Science ®Google Scholar
• Clark NM, Janaka SK, Hartman W, et al. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. PLoS ONE. 2022;17(3):e0257930. DOI:10.1371/journal.pone.0257930
   PubMed Web of Science ®Google Scholar
• Maemura T, Kuroda M, Armbrust T, et al. Antibody-Dependent Enhancement of SARS-CoV-2 Infection is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages. MBio. 2021;12(5):e0198721.
   PubMed Web of Science ®Google Scholar
• McDyer JF, Azimpouran M, Durkalski-Mauldin VL, et al. COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response. JCI Insight. 2023;8(8).
   PubMed Web of Science ®Google Scholar
• Kandathil AJ, Benner SE, Bloch EM, et al. Absence of pathogenic viruses in COVID-19 convalescent plasma. Transfusion. 2023;63(1):23–29. DOI:10.1111/trf.17168
   PubMed Web of Science ®Google Scholar
• Li PY, Yu P, Li A, et al. Convalescent plasma therapy for COVID-19 in ambulatory vs hospitalized patients: efficacy and risk of thromboembolism. Res Pract Thromb Haemost. 2023;7(2):100068.
   PubMedGoogle Scholar
• Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515).
   Web of Science ®Google Scholar
• Körper S, Grüner B, Zickler D, et al. One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. J Clin Investig. 2022;132(24).
   PubMed Web of Science ®Google Scholar
• Salazar E, Christensen PA, Graviss EA, et al. Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG. Am J Pathol. 2021;191(1):90–107. DOI:10.1016/j.ajpath.2020.10.008
   PubMed Web of Science ®Google Scholar
• Casadevall A, Scharff MD. “Serum Therapy” revisited: animal models of infection and the development of passive antibody therapy. Antimicrob Agents Chemotherap. 1994;38(8):1695–1702.
   PubMed Web of Science ®Google Scholar
• Zheng J, Wong LYR, Li K, et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature. 2021;589(7843):603–607. DOI:10.1038/s41586-020-2943-z
   PubMed Web of Science ®Google Scholar
• Golden JW, Zeng X, Cline CR, et al. Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. J Gen Virol. 2021;102(5).
   PubMed Web of Science ®Google Scholar
• Haagmans BL, Noack D, Okba NMA, et al. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model. J Infect Dis. 2021;223(12):2020–2028. DOI:10.1093/infdis/jiab289
   PubMed Web of Science ®Google Scholar
• Van Rompay KKA, Olstad KJ, Sammak RL, et al. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation. PLOS Pathog. 2022;18(4):e1009925. DOI:10.1371/journal.ppat.1009925
   PubMed Web of Science ®Google Scholar
• Deere JD, Carroll TD, Dutra J, et al. SARS-CoV-2 Infection of rhesus macaques treated early with human COVID-19 convalescent plasma. Microbiol Spectr. 2021;9(3):e0139721. DOI:10.1128/Spectrum.01397-21
   PubMed Web of Science ®Google Scholar
• McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630–634. DOI:10.1038/s41586-020-03041-6
   PubMed Web of Science ®Google Scholar
• Baum A, Ajithdoss D, Copin R, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020;370(6520):1110–1115. DOI:10.1126/science.abe2402
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;384(11):1015–1027. DOI:10.1056/NEJMoa2031893
   PubMed Web of Science ®Google Scholar
• Belov A, Huang Y, Villa CH, et al. Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy. Am J Hematol. 2022;97(6):770–779. DOI:10.1002/ajh.26531
   PubMed Web of Science ®Google Scholar
• Maor Y, Cohen D, Paran N, et al. Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. EClinicalMedicine. 2020;26:100525.
   PubMedGoogle Scholar
• Libster R, Perez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe covid-19 in older adults. N Engl J Med. 2021;384(7):610–618. DOI:10.1056/NEJMoa2033700.
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Paneth NS, Senefeld JW, et al. Concerns about estimating relative risk of death associated with convalescent plasma for COVID-19. Nature Med. 2022;28(1):51–52. DOI:10.1038/s41591-021-01638-6
   PubMed Web of Science ®Google Scholar
• González SE, Regairaz L, Salazar MR, et al. Timing of convalescent plasma administration and 28-day mortality in COVID-19 pneumonia. J Investig Med. 2022;70(5):1258–1264. DOI:10.1136/jim-2021-002158
   PubMedGoogle Scholar
• De Silvestro G, Marson P, La Raja M, et al. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: one-year of data from the Veneto region (Italy) Registry. Eur J Internal Med. 2022;97:42–49.
   PubMed Web of Science ®Google Scholar
• Arnold Egloff SA, Junglen A, Restivo JSA, et al. Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19. J Clin Investig. 2021;131(20). DOI:10.1172/JCI151788.
   PubMed Web of Science ®Google Scholar
• Gatto NM, Freund D, Ogata P, et al. Correlates of Coronavirus Disease 2019 Inpatient Mortality at a Southern California Community Hospital with a Predominantly Hispanic/Latino Adult Population. Open Forum Infect Dis. 2023;10(1):ofad011. DOI:10.1093/ofid/ofad011
   PubMed Web of Science ®Google Scholar
• Casadevall A, Dragotakes Q, Johnson PW, et al. Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. Elife. 2021;10. DOI:10.7554/eLife.69866
   PubMed Web of Science ®Google Scholar
• Troxel AB, Petkova E, Goldfeld K, et al. Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a Meta-analysis. JAMA Netw Open. 2022;5(1):e2147331. DOI:10.1001/jamanetworkopen.2021.47331
   PubMed Web of Science ®Google Scholar
• Senefeld JW, Franchini M, Mengoli C, et al. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(1):e2250647. DOI:10.1001/jamanetworkopen.2022.50647
   PubMed Web of Science ®Google Scholar
• Senefeld JW, Klassen SA, Ford SK, et al. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion. 2021;61(8):2503–2511. DOI:10.1111/trf.16525
   PubMed Web of Science ®Google Scholar
• Thompson MA, Henderson JP, Shah PK, et al. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol. 2021;7(8):1167–1175. DOI:10.1001/jamaoncol.2021.1799
   PubMed Web of Science ®Google Scholar
• Hueso T, Godron AS, Lanoy E, et al. Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis. Leukemia. 2022;36(4):1025–1034. DOI:10.1038/s41375-022-01511-6
   PubMed Web of Science ®Google Scholar
• Hueso T, Pouderoux C, Pere H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290–2295. DOI:10.1182/blood.2020008423
   PubMed Web of Science ®Google Scholar
• Denkinger CM, Janssen M, Schäkel U, et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nature Cancer. 2023;4(1):96–107. DOI:10.1038/s43018-022-00503-w.
   PubMedGoogle Scholar
• Ripoll JG, Gorman EK, Juskewitch JE, et al. Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19. Blood Adv. 2022;6(23):5951–5955. DOI:10.1182/bloodadvances.2022008932
   PubMed Web of Science ®Google Scholar
• Klein SL, Pekosz A, Park HS, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Investig. 2020;130(11):6141–6150. DOI:10.1172/JCI142004
   PubMed Web of Science ®Google Scholar
• Levine AC, Fukuta Y, Huaman MA, et al. COVID-19 convalescent plasma outpatient therapy to prevent outpatient hospitalization: a meta-analysis of individual participant data from five randomized trials. Clin Infect Dis. 2023. DOI:10.1093/cid/ciad088.
   Web of Science ®Google Scholar
• Gonzalez JLB, González Gámez M, Mendoza Enciso EA, et al. Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial. medRxiv. 2021. 2021.2003.2028.21254507.
   Google Scholar
• Focosi D, Casadevall A. Convalescent plasma in outpatients with COVID-19. Lancet Respir Med. 2022;10(3):226–228.
   PubMed Web of Science ®Google Scholar
• Shoham S, Focosi D. Limitations on PassItOn design and execution should temper negative conclusions. Chest. 2022;162(5):e282–283.
   PubMed Web of Science ®Google Scholar
• Goligher EC, Lawler PR, Jensen TP, et al. Heterogeneous treatment effects of therapeutic-dose heparin in patients hospitalized for COVID-19. JAMA. 2023;329(13):1066–1077. DOI:10.1001/jama.2023.3651
   PubMed Web of Science ®Google Scholar
• Bar KJ, Shaw PA, Choi GH, et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Investig. 2021;131(24).
   Web of Science ®Google Scholar
• Plummer N, Liebmann J, Solomon S, et al. Chemotherapy versus combined chemotherapy and serum: in the treatment of pneumonia a study of 607 alternated cases. J Am Med Assoc. 1941;116(21):2366–2371.
   Google Scholar
• Thielen PM, Wohl S, Mehoke T, et al. Genomic diversity of SARS-CoV-2 during early introduction into the Baltimore-Washington metropolitan area. JCI Insight. 2021;6(6):e144350.
   PubMed Web of Science ®Google Scholar
• Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early convalescent plasma for high-risk outpatients with covid-19. N Engl J Med. 2021;385(21):1951–1960. DOI:10.1056/NEJMoa2103784
   PubMed Web of Science ®Google Scholar
• Park H, Tarpey T, Liu M, et al. Development and validation of a treatment benefit index to identify hospitalized patients with covid-19 who may benefit from convalescent plasma. JAMA Netw Open. 2022;5(1):e2147375. DOI:10.1001/jamanetworkopen.2021.47375
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Grinsztejn B, Cummings MJ, et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J Clin Investig. 2021;131(13).
   PubMed Web of Science ®Google Scholar
• Stadler E, Chai KL, Schlub TE, et al. Determinants of passive antibody efficacy in SARS-CoV-2 infection. medRxiv. 2022;2003.2021.22272672 (2022).
   PubMedGoogle Scholar
• Bloch EM, Tobian AAR, Shoham S, et al. How do I implement an outpatient program for the administration of convalescent plasma for COVID-19? Transfusion. 2022;62(5):933–941. DOI:10.1111/trf.16871
   PubMed Web of Science ®Google Scholar
• Alemany A, Millat-Martinez P, Corbacho-Monné M, et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respir Med. 2022;10(3):278–288. DOI:10.1016/S2213-2600(21)00545-2
   PubMed Web of Science ®Google Scholar
• Ross V. Photodynamic action of methylene blue on antipneumococcal serum. J Immunol. 1938;35(5):351–369.
   Google Scholar
• Focosi D, Casadevall A. Pathogen reduction technologies need to evaluate Fc-mediated antibody functions. Transfusion. 2022;62(8):1680–1681.
   PubMed Web of Science ®Google Scholar
• Gordon O, Brosnan MK, Yoon S, et al. Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children. JCI Insight. 2022;7(2):e151518.
   PubMed Web of Science ®Google Scholar
• Focosi D, McConnell S, Casadevall A, et al. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis. 2022;22(11):e311–326.
   PubMed Web of Science ®Google Scholar
• Polizzotto MN, Nordwall J, Babiker AG, et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza a or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;7(11):951–963. DOI:10.1016/S2213-2600(19)30253-X
   Web of Science ®Google Scholar
• Huygens S, Hofsink Q, Nijhof IS, et al. Hyperimmune globulin for severely immunocompromised patients hospitalized with coronavirus disease 2019: a randomized, controlled trial. J Infect Dis. 2023;227(2):206–210. DOI:10.1093/infdis/jiac334
   PubMed Web of Science ®Google Scholar
• Focosi D, Tuccori M, Antonelli G, et al. What is the optimal usage of Covid-19 convalescent plasma donations? Clin Microb Infect. 2020;S1198-743X(20):30589.
   Google Scholar
• Sullivan DJ, Franchini M, Joyner MJ, et al. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. Nat Commun. 2022;13(1):6478.
   PubMed Web of Science ®Google Scholar
• Ordaya EE, Abu Saleh OM, Stubbs JR, et al. Vax-Plasma in Patients with Refractory COVID-19. Mayo Clin Proc. 2022;97(1):186–189.
   PubMed Web of Science ®Google Scholar
• Ferri C, Raimondo V, Gragnani L, et al. Prevalence and death rate of covid-19 in autoimmune systemic diseases in the first three pandemic waves. relationship with disease subgroups and ongoing therapies. Curr Pharm Des. 2022;28(24):2022–2028. DOI:10.2174/1381612828666220614151732
   PubMed Web of Science ®Google Scholar
• Rojas M, Anaya JM. Why will it never be known if convalescent plasma is effective for COVID-19. J Transl Autoimmun. 2020;3:100069.
   PubMedGoogle Scholar
• Franchini M, Casadevall A, Joyner MJ, et al. WHO is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients? Life (Basel). 2023;13(1):134.
   PubMed Web of Science ®Google Scholar
• Akinbami LJ, Kruszon-Moran D, Wang CY, et al. SARS-CoV-2 Serology and Self-Reported Infection Among Adults. Nat Health Nutr Exam Survey, United States MMWR Morbidity and Mortality Weekly ReportNat Health Nutr Exam Survey, United States MMWR Morbidity and mortality weekly report. 2021 AugMay [2022];71(48):1522–1525. DOI:10.15585/mmwr.mm7148a4.
   Web of Science ®Google Scholar
• Estcourt LJ, Cohn CS, Pagano MB, et al. Clinical Practice Guidelines from the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. Ann Intern Med. 2022;175(9):1310–1321. DOI:10.7326/M22-1079
   PubMed Web of Science ®Google Scholar
• Paneth N, Casadevall A, Pirofski LA, et al. WHO COVID-19 drugs guideline: reconsider using convalescent plasma. BMJ. 2022;376:o295.
   PubMedGoogle Scholar
• Cesaro S, Ljungman P, Mikulska M, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 2022;36(6):1467–1480. DOI:10.1038/s41375-022-01578-1
   PubMed Web of Science ®Google Scholar
• Beigel JH, Aga E, Elie-Turenne MC, et al. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2019;7(11):941–950. DOI:10.1016/S2213-2600(19)30199-7
   PubMed Web of Science ®Google Scholar
• van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for ebola virus disease in guinea. N Engl J Med. 2016;374(1):33–42. DOI:10.1056/NEJMoa1511812
   PubMed Web of Science ®Google Scholar
• van Griensven J, Edwards T, Baize S. Efficacy of convalescent plasma in relation to dose of ebola virus antibodies. N Engl J Med. 2016;375(23):2307–2309.
   PubMed Web of Science ®Google Scholar
• Iannizzi C, Chai KL, Piechotta V, et al. Convalescent plasma for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2023;2(2):Cd013600. DOI:10.1002/14651858.CD013600.pub5
   PubMedGoogle Scholar
• Sullivan DJ, Gebo KA, Shoham S, et al. Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma. medRxiv. 2021; 2021.2012.2010.21267485. DOI:10.1101/2021.12.10.21267485.
   Google Scholar
• Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a Randomized Clinical Trial. JAMA. 2020;324(5):460–470. DOI:10.1001/jama.2020.10044
   PubMed Web of Science ®Google Scholar
• Sullivan D, Casadevall A. COVID-19 serology data provide guidance for future deployments of convalescent plasma. MBio. 2023;e0042823. DOI:10.1128/mbio.00428-23
   PubMed Web of Science ®Google Scholar